Kazia Therapeutics LTD (KZIA)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $5.31
- As of
Kresmion compiles this page from KZIA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
KAZIA THERAPEUTICS LTD (KZIA): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-22.
See the full KZIA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for KZIA on one page. Preview it with sample data, then open it live with a free account.
Preview the KZIA dossierActive events for KZIA
- high13F: funds added
3 tracked funds increased KZIA this 2026Q2, institutional consensus
- medium13F: new position
CITADEL ADVISORS LLC new position in KZIA
- medium13F: new position
MILLENNIUM MANAGEMENT LLC new position in KZIA
- mediumEarnings below estimates
Q4-2023: Missed consensus by 272.5% - EPS $-9.5 vs $-2.55 estimate
- mediumEarnings above estimates
Q2-2025: Beat consensus by 29.5% - EPS $-12.3 vs $-17.442 estimate
FREE, NO ACCOUNT
Every event on KZIA, as it fires
You are seeing 5 of 10 events recorded on KZIA since 2026-05-30.
The five above landed across 3 days. The other 5 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.
Recent SEC filings, KZIA
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
More data on KZIA
KZIA against its peers
KZIA's net margin of -49290.5% ranks in the 12th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2024-12-31 and 2026-04-30.
| Metric | KZIA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 42000 AUD | n/a | n/a | 0 |
| Revenue YoY | -98.2% | n/a | n/a | 1 |
| Operating margin | n/a | -352.2% | n/a | 11 |
| Net margin | -49290.5% | -267.1% | 13 | 11 |
| Return on equity | n/a | -53.7% | n/a | 20 |
| 1 year | -27.6% | -48.2% | 75 | 21 |
Peers (24): OKYO, TENX, NRXS, TLSA, ATRA, TNYA, SMNR, NMRA, CHRS, CRBP, GOSS, MNOV, PLYX, GNLX, BDTX, VTVT, RLYB, NTRB, ACRV, NKTX, CSBR, CING, AVXL, COYA. Left out: CNXU (no annual filing). Fiscal periods ending between 2024-12-31 and 2026-04-30. Every figure is one full fiscal year read from one annual filing (KZIA: 20-F), reported in AUD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Cite this data
Kresmion counts the managers it follows that reported a non-option position in KZIA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on KZIA in the last 180 days.
Upstream: SEC EDGAR filings for KZIA
Kresmion, "KAZIA THERAPEUTICS LTD (KZIA) institutional holdings and SEC filings", data as of 2026-09-22, https://kresmion.com/research/KZIA. Upstream data: SEC EDGAR filings for KZIA.
Link to this data (HTML):
<a href="https://kresmion.com/research/KZIA">KAZIA THERAPEUTICS LTD (KZIA) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow KZIA on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to KZIA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.